GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Therapeutic Solutions International TSOI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 2 Nov 2026, in USD

About Therapeutic Solutions International

Its shares trade under the ticker TSOI. It has been listed since 9 June 2008. In the fiscal year to 31 December 2023, it reported revenue of $98,994 and a net loss of $2.2m. At that date it held total assets of $3.3m and shareholders' equity of $1.1m.

Therapeutic Solutions International, Inc. engages in the provision of immune modulation for the treatment of several specific diseases. The company is headquartered in Elk City, Idaho. The company went IPO on 2008-06-09. The firm is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury, and for daily health. The firm's flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The firm also sells certain nutraceuticals. The firm has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
9 Jun 2008
Employees
3

Leadership

Pay as last reported

  • Mr. Timothy DixonChairman of the Board, President, Chief Executive Officer, since 2011$365,000
  • Dr. Feng LinChief Scientific Officer$15,000
  • Ms. Famela RamosVice President - Business Development$15,100
  • Dr. James VeltmeyerChief Medical Officer$75,000
  • Dr. Thomas IchimDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • QuadraMune is a multi-patented immune-modulatory blend targeting cancers and schizophrenia.
  • Therapeutic Solutions International employs 3 full-time staff in Elk City, Idaho.
  • The company has filed patents for allogenic StemVacs and dendritic cell activation.

Weaknesses

  • The company has only 3 employees, limiting operational capacity.
  • Therapeutic Solutions International went public in 2008, indicating limited growth.
  • The firm's development stage products lack commercialization details.

Opportunities

  • Expanding immune-modulatory agents for daily health applications.
  • Developing nutraceuticals for broader market segments.
  • Patent filings for dendritic cell activation could attract partnerships.

Threats

  • Limited employee count may hinder research and development efforts.
  • IPO in 2008 suggests potential financial instability.
  • Lack of commercialized products could lead to market competition.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.